您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Deferiprone
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Deferiprone
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Deferiprone图片
CAS NO:30652-11-0
包装与价格:
包装价格(元)
1g电议
5g电议

产品介绍

化学性质

StorageStore at -20°C
M.Wt139.15
Cas No.30652-11-0
FormulaC7H9NO2
Solubilityinsoluble in DMSO; insoluble in EtOH; ≥10.96 mg/mL in H2O
Chemical Name3-hydroxy-1,2-dimethylpyridin-4-one
Canonical SMILESCC1=C(C(=O)C=CN1C)O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Deferiprone is a chelating agent with an affinity for ferric ion (iron III),binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values.

试验操作

Cell experiment:[1]

Cell lines

Ventricular myocytes isolated from 1 ~ 3 d old Sprague Dawley rats

Reaction Conditions

50, 100 and 500 μM deferiprone

Applications

Deferiprone (100 and 500 μM) rapidly entered myocytes and displaced iron from its complex with doxorubicin. Deferiprone (3 mM) also greatly reduced hydroxyl radical production by the iron(III)-doxorubicin complex in the xanthine oxidase/xanthine superoxide generating system. Therefore, deferiprone could protect against doxorubicin-induced damage to myocytes by displacing iron bound to doxorubicin, or chelating free or loosely bound iron, thus preventing site-specific iron-based oxygen radical damage.

Animal experiment:[2]

Animal models

A rabbit model of subarachnoid hemorrhage (SAH)

Dosage form

100 mg/kg

Administered orally 8 hours after SAH, with the last dose administered 8 hours before the animals were killed, for a total of five doses

Applications

Deferiprone reduced the average luminal cross-sectional area of the basilar artery by 24% in SAH rabbits, significantly attenuating the vasospastic response after SAH. Because of its stability, lipophilicity, and ability to penetrate the blood-brain barrier, deferiprone could serve as an attractive candidate for the treatment of cerebral vasospasm.

Note

The technical data provided above is for reference only.

References:

1. Barnabé N, Zastre JA, Venkataram S, et al. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radical Biology and Medicine, 2002, 33(2): 266-275.

2. Arthur AS, Fergus AH, Lanzino G, et al. Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery, 1997, 41(6): 1385-1391.